Oppenheimer reiterated its Outperform rating on shares of Neurocrine (NASDAQ:NBIX) Biosciences (NASDAQ:NBIX), currently ...

SOM intends to advance the drug into a phase 2b trial later this year, and reckons it has key advantages over Lundbeck's Xenazine (tetrabenazine), a well-established VMAT2 inhibitor used to treat ...

Based on the result, Prilenia has speculated that the drug’s effect on the main endpoint was reduced by the use of neuroleptic medications and VMAT2 inhibitor drugs used to control the ...